Kidney Week Educational Symposia-Phosphorus Control in Hemodialysis: What’s the Optimal Strategy?

Video Transcription

Video Summary

The session “Phosphorus Control in Hemodialysis Patients: What’s the Optimal Strategy?” frames hyperphosphatemia as common in dialysis and tightly linked to vascular calcification, cardiovascular events, and mortality, yet with limited trial evidence defining ideal phosphate targets. Conventional hemodialysis removes only ~500–800 mg phosphorus per session, often less than daily intake, leaving binders and diet as main therapies despite high pill burden, side effects, cost, and risks of malnutrition from restricting protein.<br /><br />Orlando Gutierrez reviews epidemiology showing a robust, graded association between higher serum phosphate and all-cause and cardiovascular mortality, supported by plausible mechanisms: vascular/valvular calcification (including medial calcification), endothelial dysfunction after high-phosphate intake, and hormonal adaptations (PTH and FGF23) that may contribute to adverse outcomes. However, he emphasizes that improving outcomes by lowering phosphate has not been proven.<br /><br />Connie Rhee focuses on balancing phosphate control with nutrition. Dietary phosphate sources differ: plant phosphate is less bioavailable than animal sources, while additives in processed foods are near 100% absorbable and often underrecognized. Because protein intake correlates with phosphorus and low protein predicts worse survival, aggressive dietary restriction may harm. She highlights strategies using higher-capacity, lower-pill-burden binders to enable adequate protein, and describes ongoing paradigm-testing trials (e.g., HILO) comparing less stringent versus standard phosphate targets.

Asset Subtitle

Joachim Ix, Orlando Gutierrez, Connie Rhee
Support is provided by an educational grant from Fresenius Medical Care Renal Therapies Group.

Keywords

hyperphosphatemia

hemodialysis

phosphate control

vascular calcification

cardiovascular mortality

phosphate binders

dietary phosphorus

FGF23

HILO trial